Avoid common mistakes on your manuscript.
Article Corrected
Zhanel GG, Calic D, Schweizer F, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 2010; 70 (7): 859-86
Correction Made
Page 877: The last sentence, right hand column, which previously read:
“The design of the second phase III trial assessing the efficacy and safety of telavancin…”
has now been corrected as follows:
“The design of the second phase III trial assessing the efficacy and safety of oritavancin...”
Note
All online versions of this article have been updated to reflect this correction.
Additional information
An Erratum for this chapter can be found at http://dx.doi.org/10.2165/11534440-000000000-00000
Rights and permissions
About this article
Cite this article
Zhanel, G.G., Calic, D. & Schweizer, F. Erratum to New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 71, 526 (2011). https://doi.org/10.2165/11591910-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11591910-000000000-00000